Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Belamaf monotherapy induced rapid responses without unexpected toxicity in...

Dr Efstathios Kastritis - National and Kapodistrian University of Athens...

$Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )$

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC...

Prof Jason J Luke - University of Pittsburgh, Pittsburgh, USA

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma ( Prof Jason J Luke - University of Pittsburgh, Pittsburgh, USA )

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post...

Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona...

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy ( Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Axi-cel improves survival in early r/r large B-cell lymphoma

Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston...

Axi-cel improves survival in early r/r large B-cell lymphoma ( Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston, USA )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam...

Teclistamab for RRMM: Long term follow up data from MajesTEC-1 ( Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam, Netherlands )

Vaccine-immunotherapy combo for high risk melanoma: New data on distant...

Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival ( Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

More from ecancer